科润生物与资深抗体专家李月华博士签订深度项目合作协议，助力科润创新转型
2021年10月29日，重庆科润生物与生物制药领域资深科学家李月华博士完成了创新生物药项目深度合作协议的签署。根据协议，李月华博士将亲自为科润生物设计完成两个Best-in-Class/First-in-Class创新生物药的开发和一个基于纳米抗体的创新长效化技术平台的建设。该合作的达成标志着科润生物进入生物药研发创新转型2.0时代。
李月华博士表示，“科润过往在产品开发方面积累的成果，充分证明了公司在新药开发方面的系统能力；团队一直坚持走差异化开发策略，可见对行业有独到的见解；多年来团队成员始终如一的坚守更是让人钦佩。此番深度合作希望可以为科润创新药开发、创新平台建设的发展助一臂之力。”
此次与李月华博士达成的深度合作，对科润新药开发的创新转型具有重大意义，有助于科润核心竞争力的全面提升。李月华博士丰富的创新药开发经验和国际化视野，将推动科润加速开发出更具临床价值和市场竞争优势的创新药。
关于李月华博士
李月华（John Li）博士，复旦大学生物化学学士，美国北卡州立大学生物医学博士，具有二十余年First-in-Class药物开发和管理经验，对原创生物药从概念到市场的全过程有深厚的理解，曾领导或参与了十多个抗体类First-in-Class药物的成功开发，是全球最早将双特异性抗体引入药物设计并推向临床的科学家之一。他曾先后在Tanox/Genentech，GSK，阿斯利康/Medimmune等国际知名药企担任研究员、资深科学家和项目总监等职，曾获得阿斯利康公司最高级别奖励-总裁奖，阿斯利康特别贡献银奖；现任徕特康生物技术公司董事长兼CEO。
关于科润生物
科润生物专注于生物技术新药研发已有20余年，深耕于原核、酵母表达技术平台，曾获国家“十一五”重大科技专项--“重大新药创制”专项资助，自主研发能力贯穿整个研发体系。
公司现有研发管理队伍具备生物新药系统开发能力，始终坚持走差异化的产品开发策略，依托于具有优势特色的技术平台，已成功开发出多个生物新药。产品管线聚焦于肿瘤和眼科两大疾病治疗领域，致力于研发填补国内空白、替代进口、患者可及的高质量新药。
{"weixin":{"label":"微信","name":"weixin","selected":true,"value":false,"sortid":"1","shareid":"weixin","sharetitle":"分享到微信","event":"shareToWeiXin","lang":"shareWeb_WeiXin"},"copy":{"label":"复制网址","name":"copy","selected":true,"value":false,"sortid":"2","shareid":"copy","sharetitle":"复制网址","event":"copy_url","lang":"shareWeb_Copy"},"qq":{"label":"QQ好友","name":"qq","selected":true,"value":false,"sortid":"2","shareid":"qq","sharetitle":"分享到QQ","event":"shareToQQ","lang":"shareWeb_QQ"},"sina_weibo":{"label":"新浪微博","name":"sina_weibo","selected":true,"value":false,"sortid":"4","shareid":"sina_weibo","sharetitle":"分享到新浪微博","event":"shareToSinaWB","lang":"shareWeb_SinaWeiBo"},"qq_zone":{"label":"QQ空间","name":"qq_zone","selected":true,"value":false,"sortid":"5","shareid":"qq_zone","sharetitle":"分享到QQ空间","event":"shareToQzone","lang":"shareWeb_QQZone"},"renren":{"label":"人人网","name":"renren","selected":true,"value":false,"sortid":"7","shareid":"renren","sharetitle":"分享到人人网","event":"shareToRenren","lang":"shareWeb_RenRen"},"douban":{"label":"豆瓣网","name":"douban","selected":true,"value":false,"sortid":"8","shareid":"douban","sharetitle":"分享到豆瓣网","event":"shareToDouban","lang":"shareWeb_DouBan"},"baidu_tieba":{"label":"百度贴吧","name":"baidu_tieba","selected":true,"value":false,"sortid":"10","shareid":"baidu_tieba","sharetitle":"分享到百度贴吧","event":"shareToTieba","lang":"shareWeb_TieBa"},"Facebook":{"label":"Facebook","name":"Facebook","selected":true,"value":true,"sortid":"11","shareid":"Facebook","sharetitle":"分享到FaceBook","event":"shareToFacebook","lang":"shareWeb_Facebook"},"Twitter":{"label":"Twitter","name":"Twitter","selected":true,"value":true,"sortid":"12","shareid":"Twitter","sharetitle":"分享到Twitter","event":"shareToTwitter","lang":"shareWeb_Twitter"},"LinkedIn":{"label":"LinkedIn","name":"LinkedIn","selected":true,"value":true,"sortid":"13","shareid":"LinkedIn","sharetitle":"分享到linkedIn","event":"shareToLinkedin","lang":"shareWeb_Linkedin"},"whatsapp":{"label":"whatsapp","name":"whatsapp","selected":true,"value":true,"sortid":"15","shareid":"whatsapp","sharetitle":"分享到whatsapp","event":"shareToWhatsapp","lang":"shareWeb_whatsapp"},"line":{"label":"line","name":"line","selected":true,"value":true,"sortid":"15","shareid":"line","sharetitle":"分享到line","event":"shareToLine","lang":"shareWeb_line"},"qq_weibo":{"label":"腾讯微博","name":"qq_weibo","selected":true,"value":true,"sortid":"3","shareid":"qq_weibo","sharetitle":"分享到腾讯微博","event":"shareToQQwb","lang":"shareWeb_QQWeiBo"},"peopleBlog":{"label":"人民微博","name":"propleBlog","selected":true,"value":true,"sortid":"14","shareid":"propleBlog","sharetitle":"分享到人民微博","event":"shareToPeopleBlog","lang":"shareWeb_peopleBlog"}}